Peripheral proteomic changes after electroconvulsive seizures in a rodent model of non-response to chronic fluoxetine

Peripheral proteomic changes after electroconvulsive seizures in a rodent model of non-response to chronic fluoxetine

Major depressive disorder (MDD) is the psychiatric disorder with the highest prevalence in the world. Pharmacological antidepressant treatment (AD), such as selective serotonin reuptake inhibitors [SSRI, i.e., fluoxetine (Flx)] is the first line of treatment for MDD. Despite its efficacy, lack of AD...

Full description

Bibliographic Details
Main Authors: Rodolphe H. Lebeau, Indira Mendez-David, Laura Kucynski-Noyau, Céline Henry, David Attali, Marion Plaze, Romain Colle, Emmanuelle Corruble, Alain M. Gardier, Raphaël Gaillard, Jean-Philippe Guilloux, Denis J. David
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-10-01
Series:Frontiers in Pharmacology
Subjects:
electroconvulsive therapy
fluoxetine
non-response
peripheral biomarkers
major depressive disorder
difficult to treat depression
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2022.993449/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2022.993449/full

Similar Items